Thiophene Carboxylic Acid

Thiophene Carboxylic Acid

SCHEMBL5740301

Cc1nn(Cc2ccccc2)c(-c2ccccc2)c1N.O=C(O)c1cccs1

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.55
KDM4E B2RXH2 2/20 0.49
SMN1; SMN2 Q16637 5/20 0.47
NPC1 O15118 1/20 0.47
TP53 P04637 1/20 0.47
MAPT P10636 1/20 0.47
RAB9A P51151 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
POLB P06746 3/20 0.46
GAA P10253 2/20 0.46
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
ADORA3 P0DMS8 1/20 0.43
ADORA2A P29274 1/20 0.43
MAPK1 P28482 1/20 0.43
DAO P14920 1/20 0.42
HTT P42858 2/20 0.42
ALDH1A1 P00352 1/20 0.42
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thiophene Carboxylic Acid SCHEMBL6068738 0.89 LMNA (0.53) LMNAKDM4ESMN1; SMN2NPC1TP53
SCHEMBL5739917 0.83 KDM4E (0.69) LMNAKDM4ESMN1; SMN2NPC1MAPT
SCHEMBL6068438 0.74 POLB (0.59) LMNAKDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL23401382 0.71 GAA (0.56) LMNAKDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL19209447 0.69 MAPK1 (0.71) LMNAKDM4ESMN1; SMN2NPC1MAPT
SCHEMBL13858651 0.69 KDM4E (0.50) KDM4ESMN1; SMN2NPC1MAPTRAB9A
SCHEMBL8035242 0.69 SMN1; SMN2 (0.53) LMNAKDM4ESMN1; SMN2MAPTRAB9A
Biphenyl SCHEMBL27580381 0.68 DAO (0.83) LMNANPC1TP53MAPTRAB9A
Biphenyl SCHEMBL27938616 0.68 DAO (0.83) LMNANPC1TP53MAPTRAB9A
SCHEMBL33942 0.68 KDM4E (0.75) LMNAKDM4ESMN1; SMN2NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7132428-B2 Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders AVENTIS PHARMACEUTICALS INC. (US) 2006-11-07 US disclosed
EP-1644371-A1 PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS Aventis Pharmaceuticals Inc. (US) 2006-04-12 EP disclosed
WO-2005012301-A1 PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2005-02-10 WO disclosed
US-20050009859-A1 Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders AVENTIS PHARMACEUTICALS INC. (US) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009859-A1 Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders PRKDC, MAP3K2, MAP3K20 LMNA 1662/4885KDM4E 3336/4885SMN1; SMN2 1475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.